GlaxoSmithKline sign
Media playback is unsupported on your device
Video

GSK reviews drug promotion strategy

GlaxoSmithKline (GSK) is making changes to its incentive schemes following a corruption scandal in China.

GlaxoSmithKline (GSK) is scrapping its incentive schemes following a corruption scandal in China.

The firm is reviewing the way new drugs are promoted and will stop paying doctors to promote its products through speaking engagements.

The company says the latest measures are unrelated to the Chinese investigation into alleged bribery.

Maryam Moshiri reports.